Lilly bolts on cancer bispecifics with $1.6bn Merus allianceAlways a big player in oncology, Eli Lilly has fallen behind some of its rivals when it comes Share XLilly bolts on cancer bispecifics with $1.6bn Merus alliancehttps://pharmaphorum.com/news/lilly-bolts-on-cancer-bispecifics-with-1-6bn-merus-alliance/
